The evidence behind inhibitor treatment with porcine factor VIII

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 1, 2002, Pages 5-8

  Lee, Christine A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Acquired; Hybrid FVIII; Inhibitor; Pharmacokinetics; Porcine FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; PORCINE BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8;

ANAMNESIS; BLEEDING; CONFERENCE PAPER; HEMOSTASIS; HUMAN; LONG TERM CARE; PORCINE PARVOVIRUS; PRIORITY JOURNAL; THROMBOCYTE AGGLUTINATION; ANIMAL; BLOOD; EVIDENCE BASED MEDICINE; HEMOPHILIA A; HOME CARE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; REVIEW; SWINE;

ANIMALS; AUTOANTIBODIES; EVIDENCE-BASED MEDICINE; FACTOR VIII; HEMOPHILIA A; HOME CARE SERVICES; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; SWINE;

EID: 19044390355     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057292     Document Type: Conference Paper

References (11)

1. Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG: Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984;663:31-41.
2. Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989;149:1381-1385.
3. Hay CR, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Tietel J, Mannucci PM, Kasper CK: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: The results of an international survey. Thromb Haemost 1996;75:25-29.
4. Hay CR, Laurian Y, Verroust F, Preston FE, Kernoff PB: Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990;76:882-886.
5. Vyas P, Pasi KJ, Lee CA: Successful long-term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII. Haemophilia 1996;2:240-243.
6. Morrison AE, Ludlam CA, Kessler C: Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81: 1513-1520.
7. Hermans C, Owens D, Longo G, Morfini M, Lee C.A: Single-dose pharmacokinetics of porcine factor VIII (Hyate C). Thromb Haemost 2002;87:352-353.
8. Lollar P, Parker ET, Curtis JE, Helgerson SL, Hoyer LW, Scott ME, Scandella D: Inhibition of human factor Villa by anti-A2 subunit antibodies. J Clin Invest 1994;93:2497-2504.
9. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989;83: 1978-1984.
10. Lollar P: Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost 1997;78:647-651.
11. Hay CRM, DiMichele D, Rivard G, Rubinger M, Cribble J: Workshop III - porcine factor VIII - continuous infusion, immune tolerance induction and prophylaxis. Haemophilia 1997; 3(suppl 3):24-30.